Cystic fibrosis in an era of genomically guided therapy.

Abstract excerpt

Although affecting only 4-5% of those with cystic fibrosis (CF), the G551D-CFTR mutation is the target of the recently approved 'orphan drug', ivacaftor. The promise of such genomically guided therapies heralds a new era in the management of CF. A phase 3 trial demonstrated significant improvements in forced expiratory volume in 1 s (FEV(1)) from baseline, average weight gain, concentration in sweat chloride and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Quinolones
• Share to Molecular Targeted Therapy